A recent clinical study found that a new once-weekly injectable drug, elorolintide, helped adults with obesity lose about 20 percent of their body weight over 48 weeks. Participants received the medicine each week along with standard lifestyle counseling. The larger doses of the treatment showed the biggest weight-loss effects; in one group, average weight dropped by over 46 pounds, with reductions in waist circumference of more than 6 inches.
Most of the side effects were mild to moderate and included nausea and fatigue, which eased over time. The drug acts on the amylin receptor, a different appetite-pathway than many existing GLP-1 treatments, suggesting a new angle for weight-management therapies.
